obiadminpharma
New Appointment of Compensation Committee Member
Date of occurrence of the change: Sep 28, 2020 Name of the functional committees: Compensation committee Name and resume of the previous position holder: Chung-Ming Chang Honorary Research Fellow of …
OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting
Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999. TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid …
TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not …
TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not …
Announcement on the change of representative of corporate director
1.Date of occurrence of the change: Aug 03, 2020 2.Name of legal person: Sheng Chen Investment Co. Ltd 3.Name and resume of the previous position holder: Lung-Yeh Cho /Executive assistant …
Announcement on resignation of Audit Committee Member
1.Date of occurrence of the change: Jul 31, 2020 2.Name of the functional committees: Audit Committee 3.Name and resume of the previous position holder: Chung-Ming Chang Honorary Research Fellow of …
Announcement on resignation of Compensation Committee Member
1.Date of occurrence of the change: Jul 31, 2020 2.Name of the functional committees: Payroll Committee 3.Name and resume of the previous position holder: Tony Chang Honorary Research Fellow of …
Announcement on resignation of independent director
1.Date of occurrence of the change: Jul 31, 2020 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): Independent director 3.Title, name …
TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies
1.Date of occurrence of the event: Jul 29, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No …
Change in Phase III clinical study design for OBI-822 targeting TNBC and will continue the study with new clinical study design
1.Date of occurrence of the event: Jul 22, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable …